Trust Point Inc. Raises Holdings in Stryker Corporation $SYK

Trust Point Inc. grew its position in Stryker Corporation (NYSE:SYK) by 681.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,480 shares of the medical technology company’s stock after acquiring an additional 11,756 shares during the quarter. Trust Point Inc.’s holdings in Stryker were worth $4,244,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently made changes to their positions in SYK. Vanguard Group Inc. lifted its holdings in shares of Stryker by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock valued at $11,917,396,000 after acquiring an additional 133,892 shares during the last quarter. State Street Corp raised its position in Stryker by 2.1% during the fourth quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock valued at $5,374,731,000 after purchasing an additional 311,507 shares during the period. Geode Capital Management LLC lifted its stake in shares of Stryker by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock valued at $2,636,238,000 after purchasing an additional 69,851 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Stryker by 22.6% during the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after purchasing an additional 1,198,665 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Stryker during the 4th quarter valued at approximately $1,822,272,000. 77.09% of the stock is currently owned by institutional investors.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP M Kathryn Fink sold 3,500 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $283.45, for a total value of $992,075.00. Following the transaction, the vice president owned 177 shares in the company, valued at $50,170.65. The trade was a 95.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 323,264 shares of company stock worth $100,659,489. Company insiders own 4.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Citigroup restated an “outperform” rating on shares of Stryker in a research report on Monday. Barclays reduced their target price on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research note on Monday, May 4th. Raymond James Financial set a $370.00 price target on shares of Stryker in a research note on Friday, July 31st. The Goldman Sachs Group reissued a “neutral” rating and issued a $361.00 price objective on shares of Stryker in a research report on Friday, May 1st. Finally, BMO Capital Markets started coverage on shares of Stryker in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and an average price target of $386.28.

Stryker Stock Up 0.4%

Shares of SYK opened at $338.85 on Friday. The firm has a market capitalization of $129.97 billion, a P/E ratio of 35.11, a P/E/G ratio of 2.15 and a beta of 0.76. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.86. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The firm has a fifty day moving average price of $320.11 and a 200-day moving average price of $334.13.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the prior year, the business posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts expect that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s payout ratio is currently 36.48%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.